- Home
- ESGL vs MURA Comparison
ESGL vs MURA Comparison
Compare ESGL & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- MURA
- Stock Information
- Founded
- ESGL 1999
- MURA 2013
- Country
- ESGL Singapore
- MURA Ireland
- Employees
- ESGL N/A
- MURA N/A
- Industry
- ESGL
- MURA
- Sector
- ESGL
- MURA
- Exchange
- ESGL Nasdaq
- MURA Nasdaq
- Market Cap
- ESGL 72.0M
- MURA 62.2M
- IPO Year
- ESGL N/A
- MURA N/A
- Fundamental
- Price
- ESGL $1.87
- MURA $3.49
- Analyst Decision
- ESGL
- MURA Strong Buy
- Analyst Count
- ESGL 0
- MURA 4
- Target Price
- ESGL N/A
- MURA $16.00
- AVG Volume (30 Days)
- ESGL 9.7K
- MURA 50.8K
- Earning Date
- ESGL 11-26-2024
- MURA 11-13-2024
- Dividend Yield
- ESGL N/A
- MURA N/A
- EPS Growth
- ESGL N/A
- MURA N/A
- EPS
- ESGL N/A
- MURA N/A
- Revenue
- ESGL $6,218,838.00
- MURA N/A
- Revenue This Year
- ESGL N/A
- MURA N/A
- Revenue Next Year
- ESGL N/A
- MURA N/A
- P/E Ratio
- ESGL N/A
- MURA N/A
- Revenue Growth
- ESGL 20.34
- MURA N/A
- 52 Week Low
- ESGL $0.41
- MURA $2.88
- 52 Week High
- ESGL $2.23
- MURA $6.25
- Technical
- Relative Strength Index (RSI)
- ESGL 51.54
- MURA 51.24
- Support Level
- ESGL $1.69
- MURA $3.31
- Resistance Level
- ESGL $1.97
- MURA $3.66
- Average True Range (ATR)
- ESGL 0.10
- MURA 0.17
- MACD
- ESGL 0.01
- MURA -0.01
- Stochastic Oscillator
- ESGL 72.22
- MURA 54.55
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd Formerly Environmental Solutions Group Holdings Ltd is a waste management, treatment and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical and electroplating companies.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.